MX2009011284A - Uso de 4-ciclopropilmetoxi-n-(3,5-dicloro-1-oxido-piridin-4-il)-5- (metoxi)piridin-2-carboxamida para el tratamiento de trastornos motores asociados a la enfermedad de parkinson. - Google Patents

Uso de 4-ciclopropilmetoxi-n-(3,5-dicloro-1-oxido-piridin-4-il)-5- (metoxi)piridin-2-carboxamida para el tratamiento de trastornos motores asociados a la enfermedad de parkinson.

Info

Publication number
MX2009011284A
MX2009011284A MX2009011284A MX2009011284A MX2009011284A MX 2009011284 A MX2009011284 A MX 2009011284A MX 2009011284 A MX2009011284 A MX 2009011284A MX 2009011284 A MX2009011284 A MX 2009011284A MX 2009011284 A MX2009011284 A MX 2009011284A
Authority
MX
Mexico
Prior art keywords
oxidopyridin
cyclopropylmethoxy
carboxamide
parkinson
dichloro
Prior art date
Application number
MX2009011284A
Other languages
English (en)
Inventor
Christine Ravinet-Trillou
Philippe Delay-Goyet
Claire Delgorge
Christine Menet
Gilles Poughon
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of MX2009011284A publication Critical patent/MX2009011284A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

La invención se refiere al uso de 4ciclopropilmetoxi-N-(3,5-diclor o-1-óxido-piridin-4-il)-5-(metoxi)piridina-2-carboxamida para la preparación de un medicamento destinado al tratamiento de trastornos motores asociados a la enfermedad de Parkinson.
MX2009011284A 2007-04-19 2008-04-16 Uso de 4-ciclopropilmetoxi-n-(3,5-dicloro-1-oxido-piridin-4-il)-5- (metoxi)piridin-2-carboxamida para el tratamiento de trastornos motores asociados a la enfermedad de parkinson. MX2009011284A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0702853A FR2915100B1 (fr) 2007-04-19 2007-04-19 Utilisation du 4-cyclopropylmethoxy-n-(3,5-dichloro-1-oxydo- pyridin-4-yl)-5-(methoxy)pyridine-2-carboxalide pour le traitement des desordres moteurs lies a la maladie de parkinson
PCT/FR2008/000534 WO2008145841A1 (fr) 2007-04-19 2008-04-16 Utilisation du 4-cyclopropylmethoxy-n-(3,5-dichloro-1 -oxydo- pyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide pour le traitement des desordres moteurs lies a la maladie de parkinson

Publications (1)

Publication Number Publication Date
MX2009011284A true MX2009011284A (es) 2009-11-02

Family

ID=38712405

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009011284A MX2009011284A (es) 2007-04-19 2008-04-16 Uso de 4-ciclopropilmetoxi-n-(3,5-dicloro-1-oxido-piridin-4-il)-5- (metoxi)piridin-2-carboxamida para el tratamiento de trastornos motores asociados a la enfermedad de parkinson.

Country Status (34)

Country Link
US (1) US20100130554A1 (es)
EP (1) EP2146714B1 (es)
JP (1) JP5386478B2 (es)
KR (2) KR101503942B1 (es)
CN (1) CN101663035B (es)
AR (1) AR066108A1 (es)
AT (1) ATE513548T1 (es)
AU (1) AU2008257322B2 (es)
BR (1) BRPI0810444A2 (es)
CA (1) CA2684174C (es)
CL (1) CL2008001136A1 (es)
CY (1) CY1111840T1 (es)
DK (1) DK2146714T3 (es)
EA (1) EA019194B1 (es)
ES (1) ES2367408T3 (es)
FR (1) FR2915100B1 (es)
HK (1) HK1141725A1 (es)
HR (1) HRP20110666T1 (es)
IL (1) IL201448A (es)
JO (1) JO2678B1 (es)
MA (1) MA31367B1 (es)
ME (1) ME00935B (es)
MX (1) MX2009011284A (es)
MY (1) MY148092A (es)
NZ (1) NZ580482A (es)
PA (1) PA8776801A1 (es)
PL (1) PL2146714T3 (es)
PT (1) PT2146714E (es)
RS (1) RS51869B (es)
SI (1) SI2146714T1 (es)
TW (1) TWI439269B (es)
UY (1) UY31035A1 (es)
WO (1) WO2008145841A1 (es)
ZA (1) ZA200907251B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2015006807A (es) * 2012-11-28 2016-01-14 Sanofi Sa Metodo de preparacion de formas cristalinas de la 4-(ciclopropilmetoxi)-n-(3,5-dicloro-1-oxidopiridin-4-il)-5-metox ipiridin-2-carboxamida y sus formas cristalinas.
US9624100B2 (en) 2014-06-12 2017-04-18 Apple Inc. Micro pick up array pivot mount with integrated strain sensing elements

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4193926A (en) * 1974-03-20 1980-03-18 Schering Aktiengesellschaft 4-(Polyalkoxy phenyl)-2-pyrrolidones
ATE218549T1 (de) * 1993-07-28 2002-06-15 Aventis Pharma Ltd Verbindungen als pde iv und tnf inhibitoren
US6177077B1 (en) * 1999-02-24 2001-01-23 Edward L. Tobinick TNT inhibitors for the treatment of neurological disorders
WO2001047915A1 (en) * 1999-12-23 2001-07-05 Icos Corporation Cyclic amp-specific phosphodiesterase inhibitors
HUP0600103A2 (en) * 2001-03-02 2006-06-28 Bristol Myers Squibb Co Co-administration of melanocortin receptor agonist and phosphodiesterase inhibitor for treatment of cyclic-amp associated disorders
WO2004005258A1 (en) * 2002-07-02 2004-01-15 Merck Frosst Canada & Co. Di-aryl-substituted-ethane pyridone pde4 inhibitors
CA2518513C (en) * 2003-03-12 2014-05-20 Celgene Corporation N-alkyl-hydroxamic acid-isoindolyl compounds and their pharmaceutical uses
AU2006257863A1 (en) * 2005-06-10 2006-12-21 F. Hoffmann-La Roche Ag Trisubstituted amines as phosphodiesterase 4 inhibitors
US20070021451A1 (en) * 2005-07-20 2007-01-25 Hamamatsu University School Of Medicine Method for preventing or treating neurologic damage after spinal cord injury

Also Published As

Publication number Publication date
EA019194B1 (ru) 2014-01-30
JP5386478B2 (ja) 2014-01-15
EA200970970A1 (ru) 2010-02-26
IL201448A0 (en) 2010-05-31
KR101503942B1 (ko) 2015-03-18
PA8776801A1 (es) 2008-11-19
CL2008001136A1 (es) 2009-01-16
CY1111840T1 (el) 2015-10-07
RS51869B (en) 2012-02-29
PT2146714E (pt) 2011-09-02
CA2684174C (fr) 2014-02-25
ES2367408T3 (es) 2011-11-03
FR2915100B1 (fr) 2009-06-05
US20100130554A1 (en) 2010-05-27
AR066108A1 (es) 2009-07-22
FR2915100A1 (fr) 2008-10-24
CN101663035B (zh) 2012-06-20
PL2146714T3 (pl) 2011-10-31
ZA200907251B (en) 2011-04-28
MY148092A (en) 2013-02-28
HK1141725A1 (es) 2010-11-19
CA2684174A1 (fr) 2008-12-04
JO2678B1 (en) 2013-03-03
KR20150004885A (ko) 2015-01-13
MA31367B1 (fr) 2010-05-03
CN101663035A (zh) 2010-03-03
EP2146714B1 (fr) 2011-06-22
BRPI0810444A2 (pt) 2016-05-31
DK2146714T3 (da) 2011-10-10
AU2008257322A1 (en) 2008-12-04
KR20090130059A (ko) 2009-12-17
JP2010524906A (ja) 2010-07-22
ATE513548T1 (de) 2011-07-15
IL201448A (en) 2014-08-31
UY31035A1 (es) 2008-11-28
EP2146714A1 (fr) 2010-01-27
AU2008257322B2 (en) 2013-06-13
TW200911247A (en) 2009-03-16
SI2146714T1 (sl) 2011-10-28
HRP20110666T1 (hr) 2011-10-31
WO2008145841A1 (fr) 2008-12-04
NZ580482A (en) 2011-10-28
ME00935B (me) 2012-06-20
TWI439269B (zh) 2014-06-01

Similar Documents

Publication Publication Date Title
MY145439A (en) Use of flibanserin for the treatment of pre-menopausal sexual desire disorders
IL202158A (en) History of Oxadiazole, Pharmaceuticals Containing Them and Their Use in the manufacture of Drugs for the Treatment of Neurological and Psychiatric Disorders
MY151048A (en) Use of flibanserin for the treatment of post-menopausal sexual desire disorders
MX2009011357A (es) Derivados de tetrahidropirido[4,3-d] pirimidinona y metodos de uso de los mismos.
WO2009071690A3 (de) 5,6-disubstituierte oxindol-derivate und ihre verwendung zur behandlung von vasopressin-abhängigen erkrankungen
WO2008097924A3 (en) Pharmaceutical compositions comprising dextromethorphan analogs for the treatment of neurological disorders
MY150931A (en) Substituted oxazolidinones and their use
WO2008104590A3 (en) Novel dosage form
MX2009009361A (es) Nueva forma de dosificacion.
MY146657A (en) Use of 4-cyclopropylmethoxy-n- (3,5-dichloro-1-oxido-pyridin-4-yl)-5-(methoxy) pyridine-2-carboxamide for the treatment of spinal cord traumas
WO2008094054A3 (en) 6, 8-dichlorchroman-3-yl-l, 3-dihydroimidazole-2-thione derivatives and their use for the treatment of cardiovascular disorders
MY148092A (en) Use of 4-cyclopropylmethoxy-n-(3,5-dichloro-1-oxidopyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide for the treatment of motor disorders related to parkinson's disease
SI1714647T1 (sl) Uporaba agomelatina pri izdelavi zdravila za zdravljenje bipolarnih motenj
GB0710277D0 (en) Use of antivirals in the treatment of medical disorders
MX2009011214A (es) Uso de 4-ciclopropilmetoxi-n-(3,5-dicloro-1-oxido-4-piridin-4-il)- 5-(metoxi)piridin-2-carboxamida para el tratamiento de los traumatismos craneales.
EP2425829A4 (en) SOLUBLE PHARMACEUTICAL FORMS OF N, N'-DIAMINODIPHENYLSULPHONE FOR OPTIMAL USE IN THE TREATMENT OF VARIOUS ILLNESSES
FR2918281B1 (fr) Medicament pour le traitement de la maladie de parkinson.
UA96278C2 (ru) Применение флибансерина для лечения расстройств полового влечения в предклимактерический период
UA97950C2 (ru) Применение флибансерина для лечения расстройств полового влечения в постклимактерический период
UA94466C2 (ru) Комбинированные препараты с содержанием slv308 и l-dopa

Legal Events

Date Code Title Description
FG Grant or registration